Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 298 clinical trials
HDR Brachytherapy 68-Ga-RM2 PET 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer (PC)

local therapy
brachytherapy
pet/mri
  • 0 views
  • 19 Feb, 2024
Diffusion Basis Spectrum Imaging of the Prostate

Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically significant prostate cancer.

biopsy of prostate
prostate cancer screening
  • 0 views
  • 19 Feb, 2024
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC.

metastasis
metastatic castration-resistant prostate cancer
measurable disease
metastatic disease
prostate cancer
  • 0 views
  • 19 Feb, 2024
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer

This phase II trial compares high-dose rate brachytherapy and stereotactic ablative radiotherapy as monotherapy in treating patients with prostate cancer that has not spread to other parts of the body (localized). High-dose rate brachytherapy delivers radiation directly into the prostate within a few minutes by a single radioactive seed through …

adenocarcinoma of prostate
stage iib prostate cancer
stage i prostate cancer ajcc v8
stage iia prostate cancer ajcc v8
alpha blocker
  • 0 views
  • 19 Feb, 2024
Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer

This is a first in human study to assess the safety, tolerability, PK, PD and preliminary efficacy of CC-94676 in men with progressive metastatic castration-resistant prostate cancer.

adenocarcinoma of prostate
endocrine therapy
metastatic castration-resistant prostate cancer
abiraterone
androgen suppression
  • 0 views
  • 19 Feb, 2024
MRI-guided Focal Laser Ablation

Magnetic resonance imaging-guided focal laser ablation of prostate cancer.

MRI
laser ablation
prostate specific antigen
transrectal ultrasound
diffusion weighted imaging
  • 0 views
  • 19 Feb, 2024
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.

hbed-cc
metastasis
adenocarcinoma of prostate
adenocarcinoma
stereotactic body radiation therapy
  • 16 views
  • 19 Feb, 2024
Cost Talk: Discussing Cancer Care Costs

The purpose of this study is to investigate whether an encounter decision aid (used during a consultation) containing cost information about options, combined with clinician training about cost discussions and available financial resources, influence surgeon-patient cost conversations, referrals to address costs, patients' financial stress, and high-quality decision-making for patients with …

cancer care
prostate specific antigen
  • 0 views
  • 19 Feb, 2024
5 Fractions of Pelvic SABR With Intra Prostatic SABR Boost:

5-fraction SABR is a feasible, well-tolerated, effective and cost effective treatment for high-intermediate and high risk prostate cancer with/without an image-guided intraprostatic boost.

adenocarcinoma
adenocarcinoma of prostate
stereotactic body radiation therapy
  • 0 views
  • 19 Feb, 2024
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

measurable disease
multiple myeloma
  • 0 views
  • 19 Feb, 2024